ALVO ALERT: Levi & Korsinsky Investigates Alvotech for Possible Securities Fraud Violations

Core Points - Alvotech is under investigation by Levi & Korsinsky for potential violations of federal securities laws [1] - On November 2, 2025, Alvotech received a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for ATV05, indicating deficiencies that need to be addressed before approval [2] - Following the CRL announcement, Alvotech's stock price dropped over 34.2%, closing at $5.03 per share on November 3, 2025 [3] Company Summary - Alvotech is facing scrutiny due to a CRL from the FDA, which has significant implications for its product approval process [2] - The company's management expressed disappointment regarding the CRL, highlighting the challenges it faces in meeting regulatory requirements [2] - The stock market reaction indicates a loss of investor confidence, as evidenced by the substantial decline in share price following the news [3]